Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Somatic mutations in cancer-related genes in chronic myeloid leukemia patients receiving asciminib

View Full Paper
Ask AI
Bookmark
Share

Authors

EKElena KuzminaOSOleg ShukhovATAnna Turkina

Discussion

Loading...

Member takes

Overview

Analysis shows somatic mutations in cancer-related genes affect asciminib efficacy in chronic myeloid leukemia patients, highlighting implications for treatment strategies.

Key Points

  • To assess the detection rate and impact of somatic mutations on asciminib therapy in CML patients with treatment failure.
  • Enrolled adult CML patients with prior TKI failure or resistance
  • Performed mutational analysis on DNA samples from patients receiving asciminib
  • Used a targeted NGS panel of cancer-related genes for sm analysis
  • Analyzed major molecular response and progression free survival based on mutation presence
  • 50% of patients had somatic mutations in cancer-related genes
  • Commonly observed mutations were in ASXL1 (35%) and DNMT3A (20%)
  • Patients with somatic mutations showed lower progression free survival compared to those without mutations

Cite This Study

Kuzmina et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd6dhttps://doi.org/10.1182/blood-2025-2000
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes2024 · 16 citations
  2. 2Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia2026
  3. 3Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples2025
  4. 4Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform2025 · 1 citations
  5. 5Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors2025